Patents by Inventor Steven G. Kultgen

Steven G. Kultgen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20230312481
    Abstract: The present disclosure includes certain substituted (phthalazin-1-ylmethyl)ureas, N-(phthalazin-1-ylmethyl)amides, and analogues thereof, and compositions comprising the same, that can be used to treat or prevent hepatitis B virus (HBV) and/or hepatitis D virus (HDV) infections in a patient.
    Type: Application
    Filed: June 7, 2021
    Publication date: October 5, 2023
    Inventors: Andrew G. Cole, Bruce D. Dorsey, Benjamin J. Dugan, Yi Fan, Steven G. Kultgen, Eugen F. Mesaros, Michael J. Sofia
  • Publication number: 20230295115
    Abstract: The present disclosure includes substituted isoquinolinylmethyl amides, or analogues thereof, and compositions comprising the same, that can be used to treat, ameliorate, and/or prevent hepatitis B virus (HBV) and/or hepatitis D virus (HDV) infections in a patient.
    Type: Application
    Filed: June 7, 2021
    Publication date: September 21, 2023
    Inventors: Andrew G. Cole, Bruce D. Dorsey, Benjamin J. Dugan, Yi Fan, Steven G. Kultgen, Eugen F. Mesaros, Michael J. Sofia
  • Publication number: 20230108906
    Abstract: The present disclosure includes in one aspect substituted arylmethyl ureas, substituted heteroarylmethyl ureas, or analogues thereof, and compositions comprising the same, that can be used to treat or prevent hepatitis B virus (HBV) and/or hepatitis D virus (HDV) infections in a patient.
    Type: Application
    Filed: December 18, 2020
    Publication date: April 6, 2023
    Inventors: Andrew G. Cole, Bruce D. Dorsey, Yi Fan, Steven G. Kultgen, Eugen F. Mesaros
  • Patent number: 11236055
    Abstract: The present invention relates to sulfonamide compounds of formula (I) and formula (II), or a pharmaceutically acceptable salt thereof. The present sulfonamide compounds are useful non-systemic TGR5 agonists that can be used to treat diabetic diseases in human. The present invention provides a pharmaceutical composition containing sulfonamide compounds of formula (I) and formula (II) and a method of making as well as a method of using same in treating patients inflicted with metabolic disorders by administering same. The compounds of the present invention may be used in combination with additional anti-diabetic drugs.
    Type: Grant
    Filed: June 29, 2017
    Date of Patent: February 1, 2022
    Assignee: VENENUM BIODESIGN, LLC
    Inventors: Chia-Yu Huang, Brian F. McGuinness, Dongchuan Shi, Steven G. Kultgen, Jeffrey J. Letourneau, James R. Beasley, Philip D. Stein, Andrew G. Cole
  • Publication number: 20210238183
    Abstract: The present invention provides protein kinase having one of the following structures (I), (II) or (III): or a stereoisomer, prodrug, tautomer or pharmaceutically acceptable salt thereof, wherein R, R1, R2 and X are as defined herein. Compositions and methods for using the same in the treatment of cancer, autoimmune, inflammatory and other Pim kinase-associated conditions are also disclosed.
    Type: Application
    Filed: November 5, 2020
    Publication date: August 5, 2021
    Inventors: Yong Xu, Benjamin Gary Brenning, Steven G. Kultgen, Xiaohui Liu, Michael David Saunders, Koc-Kan Ho
  • Patent number: 10875864
    Abstract: The present invention provides a compound having the following structure: Compositions and methods for using the same in the treatment of skin disorders and other Pim kinase-associated conditions are also disclosed.
    Type: Grant
    Filed: July 2, 2019
    Date of Patent: December 29, 2020
    Assignee: SUMITOMO DAINIPPON PHARMA ONCOLOGY, INC.
    Inventors: Yong Xu, Benjamin Gary Brenning, Steven G. Kultgen, Xiaohui Liu, Michael David Saunders, Koc-Kan Ho
  • Publication number: 20200308122
    Abstract: The present invention relates to sulfonamide compounds of formula (I) and formula (II), or a pharmaceutically acceptable salt thereof. The present sulfonamide compounds are useful non-systemic TGR5 agonists that can be used to treat diabetic diseases in human. The present invention provides a pharmaceutical composition containing sulfonamide compounds of formula (I) and formula (II) and a method of making as well as a method of using same in treating patients inflicted with metabolic disorders by administering same. The compounds of the present invention may be used in combination with additional anti-diabetic drugs.
    Type: Application
    Filed: June 29, 2017
    Publication date: October 1, 2020
    Applicant: Venenum Biodesign, LLC
    Inventors: Chia-Yu Huang, Brian F. McGuinness, Dongchuan Shi, Steven G. Kultgen, Jeffrey J. Letourneau, James R. Beasley, Philip D. Stein, Andrew G. Cole
  • Patent number: 10654834
    Abstract: The present invention relates to tricyclic compounds of formula (I) and formula (II), or a pharmaceutically acceptable salt thereof. The present tricyclic compounds are useful non-systemic TGR5 agonists that can be used to treat diabetic diseases in human. The present invention provides a pharmaceutical composition containing tricyclic compounds of formula (I) and formula (II) and a method of making as well as a method of using same in treating patients inflicted with metabolic disorders by administering same. The compounds of the present invention may be used in combination with additional anti-diabetic drugs.
    Type: Grant
    Filed: June 29, 2017
    Date of Patent: May 19, 2020
    Assignee: Venenum Biodesign, LLC
    Inventors: Chia-Yu Huang, Brian F. McGuinness, Xiaoqing Xu, Steven G. Kultgen, Ellen Sieber McMaster, James R. Beasley
  • Publication number: 20200102313
    Abstract: The present invention provides protein kinase having one of the following structures (I), (II) or (III): or a stereoisomer, prodrug, tautomer or pharmaceutically acceptable salt thereof, wherein R, R1, R2 and X are as defined herein. Compositions and methods for using the same in the treatment of cancer, autoimmune, inflammatory and other Pim kinase-associated conditions are also disclosed.
    Type: Application
    Filed: July 2, 2019
    Publication date: April 2, 2020
    Inventors: Yong Xu, Benjamin Gary Brenning, Steven G. Kultgen, Xiaohui Liu, Michael David Saunders, Koc-Kan Ho
  • Publication number: 20190330191
    Abstract: The present invention relates to tricyclic compounds of formula (I) and formula (II), or a pharmaceutically acceptable salt thereof. The present tricyclic compounds are useful non-systemic TGR5 agonists that can be used to treat diabetic diseases in human. The present invention provides a pharmaceutical composition containing tricyclic compounds of formula (I) and formula (II) and a method of making as well as a method of using same in treating patients inflicted with metabolic disorders by administering same. The compounds of the present invention may be used in combination with additional anti-diabetic drugs.
    Type: Application
    Filed: June 29, 2017
    Publication date: October 31, 2019
    Applicant: Venenum Biodesign, LLC
    Inventors: Chia-Yu Huang, Brian F. McGuinness, Xiaoqing Xu, Steven G. Kultgen, Ellen Sieber McMaster, James R. Beasley
  • Patent number: 10392392
    Abstract: The present invention provides substituted imidazo[1,2-b]pyridazines that are useful as protein kinase inhibitors and have one of the following structures (I), (II) or (III): or a stereoisomer, prodrug, tautomer or pharmaceutically acceptable salt thereof, wherein R, R1, R2 and X are as defined herein. For example, a compound having the following structure: Compositions and methods for using the same in the treatment of cancer, autoimmune, inflammatory and other Pim kinase-associated conditions are also disclosed.
    Type: Grant
    Filed: July 11, 2018
    Date of Patent: August 27, 2019
    Assignee: Tolero Pharmaceuticals, Inc.
    Inventors: Yong Xu, Benjamin Gary Brenning, Steven G. Kultgen, Xiaohui Liu, Michael David Saunders, Koc-Kan Ho
  • Publication number: 20190071446
    Abstract: The present invention provides protein kinase having one of the following structures (I), (II) or (III): or a stereoisomer, prodrug, tautomer or pharmaceutically acceptable salt thereof, wherein R, R1, R2 and X are as defined herein. Compositions and methods for using the same in the treatment of cancer, autoimmune, inflammatory and other Pim kinase-associated conditions are also disclosed.
    Type: Application
    Filed: July 11, 2018
    Publication date: March 7, 2019
    Inventors: Yong Xu, Benjamin Gary Brenning, Steven G. Kultgen, Xiaohui Liu, Michael David Saunders, Koc-Kan Ho
  • Patent number: 10047093
    Abstract: The present invention provides protein kinase having one of the following structures (I), (II) or (III): or a stereoisomer, prodrug, tautomer or pharmaceutically acceptable salt thereof, wherein R, R1, R2 and X are as defined herein. Compositions and methods for using the same in the treatment of cancer, autoimmune, inflammatory and other Pim kinase-associated conditions are also disclosed.
    Type: Grant
    Filed: July 11, 2016
    Date of Patent: August 14, 2018
    Assignee: TOLERO PHARMACEUTICALS, INC.
    Inventors: Yong Xu, Benjamin Gary Brenning, Steven G. Kultgen, Xiaohui Liu, Michael David Saunders, Koc-Kan Ho
  • Publication number: 20170002014
    Abstract: The present invention provides protein kinase having one of the following structures (I), (II) or (III): or a stereoisomer, prodrug, tautomer or pharmaceutically acceptable salt thereof, wherein R, R1, R2 and X are as defined herein. Compositions and methods for using the same in the treatment of cancer, autoimmune, inflammatory and other Pim kinase-associated conditions are also disclosed.
    Type: Application
    Filed: July 11, 2016
    Publication date: January 5, 2017
    Inventors: Yong Xu, Benjamin Gary Brenning, Steven G. Kultgen, Xiaohui Liu, Michael David Saunders, Koc-Kan Ho
  • Patent number: 9416132
    Abstract: The present invention provides protein kinase having one of the following structures (I), (II) or (III): or a stereoisomer, prodrug, tautomer or pharmaceutically acceptable salt thereof, wherein R, R1, R2 and X are as defined herein. Compositions and methods for using the same in the treatment of cancer, autoimmune, inflammatory and other Pim kinase-associated conditions are also disclosed.
    Type: Grant
    Filed: July 20, 2012
    Date of Patent: August 16, 2016
    Assignee: Tolero Pharmaceuticals, Inc.
    Inventors: Yong Xu, Benjamin Gary Brenning, Steven G. Kultgen, Xiaohui Liu, Michael Saunders, Koc-Kan Ho
  • Publication number: 20140329807
    Abstract: The present invention provides protein kinase having one of the following structures (I), (II) or (III): or a stereoisomer, prodrug, tautomer or pharmaceutically acceptable salt thereof, wherein R, R1, R2 and X are as defined herein. Compositions and methods for using the same in the treatment of cancer, autoimmune, inflammatory and other Pim kinase-associated conditions are also disclosed.
    Type: Application
    Filed: July 20, 2012
    Publication date: November 6, 2014
    Applicant: TOLERO PHARMACEUTICALS, INC.
    Inventors: Yong Xu, Benjamin Gary Brenning, Steven G. Kultgen, Xiaohui Liu, Michael Saunders, Koc-Kan Ho
  • Patent number: 8211927
    Abstract: The present invention relates to isoxazole-3-carboxamide derivative having the general Formula (I), or a pharmaceutically acceptable salt thereof, to pharmaceutical compositions comprising the same, as well as to the use of said isoxazole-3-carboxamide derivatives for the treatment of TRPV1 mediated disorders, such as acute and chronic pain disorders, acute and chronic neuropathic pain, acute and chronic inflammatory pain, respiratory diseases, and lower urinary tract disorders.
    Type: Grant
    Filed: July 31, 2008
    Date of Patent: July 3, 2012
    Assignee: MSD, Oss B.V.
    Inventors: Andrew Laird Roughton, Koc-Kan Ho, Michael Ohlmeyer, Irina Neagu, Steven G. Kultgen, Nasrin Ansari, Yajing Rong, Paul David Ratcliffe, Ronald Palin
  • Publication number: 20120071481
    Abstract: The present invention relates to isoxazole-3-carboxamide derivative having the general Formula I or a pharmaceutically acceptable salt thereof, to pharmaceutical compositions comprising the same, as well as to the use of said isoxazole-3-carboxamide derivatives for the treatment of TRPV1 mediated disorders, such as acute and chronic pain disorders, acute and chronic neuropathic pain, acute and chronic inflammatory pain, respiratory diseases, and lower urinary tract disorders.
    Type: Application
    Filed: February 2, 2010
    Publication date: March 22, 2012
    Inventors: Ronald Palin, Paul David Ratcliffe, Steven G. Kultgen, Koc-Kan Ho, Andrew Laird Roughton
  • Publication number: 20120058997
    Abstract: The present invention provides protein kinase inhibitors comprising imidazo[1,2-b]pyridazine and pyrazolo[1,5-a]pyrimidine compounds of the following structure (I) and (II): or a stereoisomer, prodrug or pharmaceutically acceptable salt thereof, wherein R, R1, R2 and X are as defined herein. Compositions and methods for using the same in the treatment of cancer and other Pim kinase-associated conditions are also disclosed.
    Type: Application
    Filed: July 21, 2011
    Publication date: March 8, 2012
    Applicant: SuperGen, Inc.
    Inventors: Yong Xu, Benjamin G. Brenning, Steven G. Kultgen, Xiaohui Liu, Michael Saunders, Koc-Kan Ho
  • Patent number: 7960365
    Abstract: The invention provides for compounds having the structure according to the formula I wherein: X is a carbon or nitrogen atom; Ar is phenyl or heteroaromatic ring; R1 is hydrogen, halogen, CN or (1C-4C)alkyl; R2 is hydrogen, halogen or optionally fluorinated (1C-3C)alkoxy; R3 and R5 are independently hydrogen, optionally halogenated (1C-4C)alkyl, optionally halogenated (1C-4C)alkoxy, optionally halogenated aryl(1C-4C)alkoxy, optionally halogenated (1C-4C)alkenyl or hydroxylmethyl; R4 is hydrogen, halogen, optionally halogenated (1C-4C)alkoxy or optionally halogenated aryl(1C-4C)alkoxy; R6 is hydrogen, benzyl, optionally substituted with one or more halogens or (1C-4C)alkyl, or R6 is optionally halogenated (1C-4C)alkyl; each R7 independently is hydrogen, halogen, optionally halogenated (1C-4C)alkyl or optionally halogenated (1C-4C)alkoxy and pharmaceutically suitable acid addition salts thereof for use as glucocorticoid receptor modulators, in particular for treatment of central nervous system disorders.
    Type: Grant
    Filed: December 19, 2006
    Date of Patent: June 14, 2011
    Assignee: N.V. Organon
    Inventors: Niall Morton Hamilton, Simon James Anthony Grove, Michael John Kiczun, John Richard Morphy, Brad Sherborne, Peter Thomas Albert Littlewood, Angus Richard Brown, Celia Kingsbury, Michael Ohhlmeyer, Koc-Kan Ho, Steven G. Kultgen